A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation

Figure 1 Participant flow.

Figure 2 Change from baseline in the number of CSBMs per week (wk 1-4) by treatment (ITT population). Footnote: ^bP = 0.0002 vs placebo; Mean number of CSBMs per week at baseline: tegaserod 0.36; placebo 0.31.

Figure 3 Change from baseline in the number of CSBMs per week by study week and treatment (ITT population). Footnote: ^aP < 0.05 vs placebo; Mean number of CSBMs per week at baseline: tegaserod 0.36; placebo 0.31.

Figure 4 A: Response rate relative to baseline (increase of ≥ 1 CSBM per week) by week (ITT population); B: Absolute response rate (increase of ≥ 3 CSBM per week) (ITT population). ^aP < 0.05 vs placebo; Mean number of CSBMs per week at baseline: tegaserod 0.36; placebo 0.31.

Figure 5 Change from baseline in number of SBMs per week by study week and treatment (ITT population). ^aP < 0.05 vs placebo; Mean number of SBMs per week at baseline: tegaserod 2.33; placebo 2.26.

Figure 6 Change from baseline in number of days per week with no stool, hard, or very hard stools by treatment (ITT population). ^aP < 0.05 vs placebo; An improvement was defined as a decrease in the number of days with no stool, hard, or very hard stools (Bristol stool score of 1 or 2[19]) relative to baseline.

Figure 7 Satisfactory relief of constipation symptoms by week and treatment period (ITT population). ^aP < 0.05 vs placebo.